Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases

Pitfalls and helpful tricks in a review for clinicians

Filippo Pietrantonio, Armando Orlandi, Alessandro Inno, Valentina Da Prat, Daniele Spada, Alessandro Iaculli, Maria Di Bartolomeo, Carlo Morosi, Filippo de Braud

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Bevacizumab added to chemotherapy has shown encouraging efficacy in the neoadjuvant therapy of colorectal cancer liver metastases. In absence of biological predictor factors of efficacy to bevacizumab-based treatment, the assessment of response may be a crucial point to select patients who may benefit the most from surgery. At the same time the pathological response after liver resection could represent a guide for the next therapeutic plan. In the pre-surgical phase, conventional computed tomography and response evaluation with RECIST criteria may underestimate the response to anti-angiogenic drugs. Modified computed tomography criteria of response, morphologic changes as well as novel imaging techniques and metabolic assessment by fluorodeoxyglucose positron emission tomography seem to be promising methods for the assessment of response and for leading the clinical choices. Pathological response at the time of surgery is an important prognostic factor and a surrogate of survival for resected patients. Different classification criteria to assess pathological response have been developed, residual viable tumor, tumor regression grade (TRG), modified TRG and tumor thickness at the tumor-normal interface, but to date a superiority of one approach over the others has not been clearly established. In this review, we evaluate the available data with the aim to help the clinicians in the pre- and post-surgical care of patient with colorectal cancer liver metastases treated with bevacizumab-based neoadjuvant strategy.

Original languageEnglish
Pages (from-to)272-281
Number of pages10
JournalCritical Reviews in Oncology/Hematology
Volume95
Issue number3
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Liver Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Drug Therapy
Neoplasms
Tomography
Neoadjuvant Therapy
Angiogenesis Inhibitors
Residual Neoplasm
Biological Factors
Positron-Emission Tomography
Patient Care
Survival
Bevacizumab
Liver
Therapeutics

Keywords

  • Bevacizumab
  • Colorectal cancer
  • Liver metastases
  • Neoadjuvant
  • Response criteria

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases : Pitfalls and helpful tricks in a review for clinicians. / Pietrantonio, Filippo; Orlandi, Armando; Inno, Alessandro; Da Prat, Valentina; Spada, Daniele; Iaculli, Alessandro; Di Bartolomeo, Maria; Morosi, Carlo; de Braud, Filippo.

In: Critical Reviews in Oncology/Hematology, Vol. 95, No. 3, 01.09.2015, p. 272-281.

Research output: Contribution to journalArticle

Pietrantonio, Filippo ; Orlandi, Armando ; Inno, Alessandro ; Da Prat, Valentina ; Spada, Daniele ; Iaculli, Alessandro ; Di Bartolomeo, Maria ; Morosi, Carlo ; de Braud, Filippo. / Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases : Pitfalls and helpful tricks in a review for clinicians. In: Critical Reviews in Oncology/Hematology. 2015 ; Vol. 95, No. 3. pp. 272-281.
@article{99da7b517405412ea483fdcd69bf7814,
title = "Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians",
abstract = "Bevacizumab added to chemotherapy has shown encouraging efficacy in the neoadjuvant therapy of colorectal cancer liver metastases. In absence of biological predictor factors of efficacy to bevacizumab-based treatment, the assessment of response may be a crucial point to select patients who may benefit the most from surgery. At the same time the pathological response after liver resection could represent a guide for the next therapeutic plan. In the pre-surgical phase, conventional computed tomography and response evaluation with RECIST criteria may underestimate the response to anti-angiogenic drugs. Modified computed tomography criteria of response, morphologic changes as well as novel imaging techniques and metabolic assessment by fluorodeoxyglucose positron emission tomography seem to be promising methods for the assessment of response and for leading the clinical choices. Pathological response at the time of surgery is an important prognostic factor and a surrogate of survival for resected patients. Different classification criteria to assess pathological response have been developed, residual viable tumor, tumor regression grade (TRG), modified TRG and tumor thickness at the tumor-normal interface, but to date a superiority of one approach over the others has not been clearly established. In this review, we evaluate the available data with the aim to help the clinicians in the pre- and post-surgical care of patient with colorectal cancer liver metastases treated with bevacizumab-based neoadjuvant strategy.",
keywords = "Bevacizumab, Colorectal cancer, Liver metastases, Neoadjuvant, Response criteria",
author = "Filippo Pietrantonio and Armando Orlandi and Alessandro Inno and {Da Prat}, Valentina and Daniele Spada and Alessandro Iaculli and {Di Bartolomeo}, Maria and Carlo Morosi and {de Braud}, Filippo",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.critrevonc.2015.04.008",
language = "English",
volume = "95",
pages = "272--281",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases

T2 - Pitfalls and helpful tricks in a review for clinicians

AU - Pietrantonio, Filippo

AU - Orlandi, Armando

AU - Inno, Alessandro

AU - Da Prat, Valentina

AU - Spada, Daniele

AU - Iaculli, Alessandro

AU - Di Bartolomeo, Maria

AU - Morosi, Carlo

AU - de Braud, Filippo

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Bevacizumab added to chemotherapy has shown encouraging efficacy in the neoadjuvant therapy of colorectal cancer liver metastases. In absence of biological predictor factors of efficacy to bevacizumab-based treatment, the assessment of response may be a crucial point to select patients who may benefit the most from surgery. At the same time the pathological response after liver resection could represent a guide for the next therapeutic plan. In the pre-surgical phase, conventional computed tomography and response evaluation with RECIST criteria may underestimate the response to anti-angiogenic drugs. Modified computed tomography criteria of response, morphologic changes as well as novel imaging techniques and metabolic assessment by fluorodeoxyglucose positron emission tomography seem to be promising methods for the assessment of response and for leading the clinical choices. Pathological response at the time of surgery is an important prognostic factor and a surrogate of survival for resected patients. Different classification criteria to assess pathological response have been developed, residual viable tumor, tumor regression grade (TRG), modified TRG and tumor thickness at the tumor-normal interface, but to date a superiority of one approach over the others has not been clearly established. In this review, we evaluate the available data with the aim to help the clinicians in the pre- and post-surgical care of patient with colorectal cancer liver metastases treated with bevacizumab-based neoadjuvant strategy.

AB - Bevacizumab added to chemotherapy has shown encouraging efficacy in the neoadjuvant therapy of colorectal cancer liver metastases. In absence of biological predictor factors of efficacy to bevacizumab-based treatment, the assessment of response may be a crucial point to select patients who may benefit the most from surgery. At the same time the pathological response after liver resection could represent a guide for the next therapeutic plan. In the pre-surgical phase, conventional computed tomography and response evaluation with RECIST criteria may underestimate the response to anti-angiogenic drugs. Modified computed tomography criteria of response, morphologic changes as well as novel imaging techniques and metabolic assessment by fluorodeoxyglucose positron emission tomography seem to be promising methods for the assessment of response and for leading the clinical choices. Pathological response at the time of surgery is an important prognostic factor and a surrogate of survival for resected patients. Different classification criteria to assess pathological response have been developed, residual viable tumor, tumor regression grade (TRG), modified TRG and tumor thickness at the tumor-normal interface, but to date a superiority of one approach over the others has not been clearly established. In this review, we evaluate the available data with the aim to help the clinicians in the pre- and post-surgical care of patient with colorectal cancer liver metastases treated with bevacizumab-based neoadjuvant strategy.

KW - Bevacizumab

KW - Colorectal cancer

KW - Liver metastases

KW - Neoadjuvant

KW - Response criteria

UR - http://www.scopus.com/inward/record.url?scp=84938485242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938485242&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.04.008

DO - 10.1016/j.critrevonc.2015.04.008

M3 - Article

VL - 95

SP - 272

EP - 281

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -